Recurrent Cervical Carcinoma
Showing 1 - 25 of >10,000
Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,
Terminated
- Recurrent Gynecological Cancer
- +10 more
- Durvalumab
- +2 more
-
Boston, MassachusettsMartin King
Oct 4, 2022
Targeted Therapy, Chemo, Recurrent Cervical Carcinoma Trial in Beijing (Donafenib combined with paclitaxel and platinum ± PD-1
Recruiting
- Targeted Therapy
- +6 more
- Donafenib combined with paclitaxel and platinum ± PD-1 antibody
-
Beijing, Beijing, ChinaLei Li
Mar 26, 2022
Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma Trial in Beijing (Tislelizumab plus
Recruiting
- Recurrent Cervical Carcinoma
- +9 more
- Tislelizumab plus radiotherapy
-
Beijing, Beijing, ChinaLei Li
Apr 1, 2022
Human Papilloma Virus Circulating Tumor DNA in Cervical Cancer
Recruiting
- Cervical Adenosquamous Carcinoma
- +26 more
- Biospecimen Collection
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Recruiting
- Immune Checkpoint Inhibitors
- +9 more
- Radiotherapy for targeted lesions and PD-1 antibody
-
Beijing, Beijing, ChinaLei Li
Apr 1, 2022
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Chemotherapy plus apatinib)
Completed
- Recurrent Cervical Carcinoma
- +5 more
- Chemotherapy plus apatinib
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (A combination of anti-PD-1
Completed
- Recurrent Cervical Carcinoma
- +4 more
- A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Anti-PD-1 antibody camrelizumab,
Recruiting
- Recurrent Cervical Carcinoma
- +5 more
- Anti-PD-1 antibody camrelizumab
- Albumin-bound paclitaxel
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy Trial run by the Precigen, Inc (PRGN-2009 plus Pembrolizumab,
Not yet recruiting
- Cervical Cancer
- +2 more
- PRGN-2009 plus Pembrolizumab
- Pembrolizumab alone
-
Bethesda, MarylandNational Institute of Health
Nov 27, 2023
Malignant Female Reproductive System Tumor, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma Trial in Houston
Recruiting
- Malignant Female Reproductive System Neoplasm
- +24 more
- Quality-of-Life Assessment
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jun 6, 2022
Ovarian Tumors, Endometrial Tumors, Uterine Cervical Tumors Trial (Dostarlimab, Bevacizumab, Doxorubicin)
Not yet recruiting
- Ovarian Neoplasms
- +5 more
- Dostarlimab
- +4 more
- (no location specified)
Sep 3, 2023
MRI and PET Imaging in Predicting Treatment Response in Stage
Active, not recruiting
- Cervical Adenocarcinoma
- +12 more
- Computed Tomography
- +5 more
-
Miami, Florida
- +5 more
Oct 4, 2022
HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer Trial (VB10.16, Atezolizumab Injection [Tecentriq],
Not yet recruiting
- HPV-Related Cervical Carcinoma
- +2 more
- VB10.16
- +2 more
- (no location specified)
Oct 24, 2023
Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer Trial in Shanghai (SHR-1210, Famitinib)
Recruiting
- Renal Cell Carcinoma
- +4 more
- SHR-1210
- Famitinib
-
Shanghai, Shanghai, ChinaHuadong Hospital Affiliated to Fudan University
Jun 30, 2022
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Tumor Trial in Houston (DNA
Active, not recruiting
- Human Papillomavirus-16 Positive
- +20 more
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457
- Durvalumab
-
Houston, TexasM D Anderson Cancer Center
Feb 11, 2022
Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma, Locally Advanced Rectal Carcinoma Trial in Duarte (procedure,
Recruiting
- Localized Prostate Carcinoma
- +17 more
- Biospecimen Collection
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 1, 2023
Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor Trial in Beijing (Combination of nimotuzumab and
Recruiting
- Recurrent Cervical Carcinoma
- +6 more
- Combination of nimotuzumab and radiotherapy
-
Beijing, Beijing, ChinaLei Li
Dec 18, 2020
Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC) Trial in Gainesville, Jacksonville (LITT +
Recruiting
- Melanoma
- +14 more
- LITT + Pembrolizumab
-
Gainesville, Florida
- +1 more
Aug 22, 2022
Chemo, Anti-pd-1 Antibody, Cervical Neuroendocrine Carcinoma Trial in Beijing (Drug therapy)
Recruiting
- Chemotherapy
- +6 more
- Drug therapy
-
Beijing, Beijing, ChinaLei Li
Nov 15, 2020
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (ONM-501, Cemiplimab)
Not yet recruiting
- Triple Negative Breast Cancer
- +13 more
- (no location specified)
Aug 29, 2023
Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer Trial in Oklahoma City (VS-6766 + defactinib)
Not yet recruiting
- Endometrioid Cancer
- +3 more
- VS-6766 + defactinib
-
Oklahoma City, OklahomaStephenson Cancer Center
Aug 19, 2022
Squamous Cell Lung Cancer, Vulvar Cancer, Penile Cancer Trial in France (pembrolizumab; vorinostat)
Active, not recruiting
- Squamous Cell Lung Cancer
- +5 more
- pembrolizumab; vorinostat
-
Angers, France
- +13 more
Jan 4, 2023
Uterine Cervical Tumors Trial in Worldwide (Nintedanib, Placebo)
Active, not recruiting
- Uterine Cervical Neoplasms
- Nintedanib
- Placebo
-
Bruxelles, Belgium
- +31 more
Mar 1, 2022